Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OT 82

Drug Profile

OT 82

Alternative Names: OT-82

Latest Information Update: 20 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTartis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma
  • Preclinical Haematological malignancies

Most Recent Events

  • 16 Jan 2020 OncoTartis plans a clinical trial in Precursor cell lymphoblastic leukaemia lymphoma (PO)
  • 29 Mar 2019 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 18 Apr 2018 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top